

## Total Synthesis of SS20846A via Intramolecular Pd(II)-Catalyzed Cyclization


Hajime Yokoyama, Kumiko Otaya, Seiji Yamaguchi and Yoshiro Hirai\*

Department of Chemistry, Toyama University, Gofuku 3190, Toyama 930, Japan

Received 22 April 1998; revised 8 June 1998; accepted 12 June 1998


**Abstract:** A stereoselective total synthesis of SS20846A was efficiently accomplished by means of an intramolecular palladium(II)-catalyzed cyclization. © 1998 Elsevier Science Ltd. All rights reserved.

SS20846A (**1**) is a biologically active piperidine alkaloid isolated from *Streptomyces* sp. S20846<sup>1,2)</sup>. It is also a biosynthetic intermediate of streptazolin<sup>3,4)</sup>. For several years we have been investigating the stereoselective construction of nitrogen hetero-alicycles via the intramolecular palladium(II)-catalyzed cyclization<sup>5,6,7)</sup>, focusing on the challenging direct construction of *trans*-2,4-disubstituted piperidines such as **1** from acyclic precursors. We report here a novel stereoselective synthesis of SS20846A (**1**) by the intramolecular cyclization of the corresponding urethane using palladium(II) catalyst.




The substrate **2** for palladium(II)-catalyzed cyclization was prepared from (*S*)-glycidol (Scheme 1)<sup>8)</sup>. Addition of [tetrahydro-2-(2-proynyoxy)-2*H*-pyran]-2-propyne to (*R*)-*O*-*t*-butyldimethylsilyl glycidol **3**, which was readily prepared from (*S*)-glycidol, in the presence of *n*-BuLi and TMEDA at -78°C gave the alcohol **4** in 34% yield. Deprotection of the alcohol **4** (TBAF, THF; 97% yield), mono-tosylation of the resulting diol **5** (TsCl, pyridine, CH<sub>2</sub>Cl<sub>2</sub>; 52% yield) and epoxidation of the tosylate **6** (K<sub>2</sub>CO<sub>3</sub>, MeOH; 86% yield) provided the epoxide **7** in 15% overall yield. The ring opening of the epoxide **7** by treatment with

potassium cyanide (KCN, sat. MgSO<sub>4</sub> aq., MeOH, 99% yield) followed by protection of the resulting alcohol **8** (TBSCl, imidazole, DMF; 99% yield) gave the nitrile **9**. Reduction of the cyano group (LAH, THF) and the subsequent protection of the amine **10** ((Boc)<sub>2</sub>O, Et<sub>3</sub>N, CH<sub>2</sub>Cl<sub>2</sub>) gave the urethane **11** in 39% overall yield. The treatment of **11** with PPTS in MeOH at r.t. followed by hydrogenation of the resulting alcohol **12** afforded the desired substrate **2** in 47% yield<sup>9</sup>.




**Scheme 1** a) CH≡CCH<sub>2</sub>OTHP, *n*-BuLi, TMEDA, THF, -78 °C, 34%; b) TBAF, THF, 0 °C, 97%; c) TsCl, Pyridine, CH<sub>2</sub>Cl<sub>2</sub>, r.t., 52%; d) K<sub>2</sub>CO<sub>3</sub>, MeOH, 0 °C, 86%; e) KCN, MeOH, sat. MgSO<sub>4</sub> aq., r.t., 99%; f) TBSCl, imidazole, DMF, r.t., 99%; g) LiAlH<sub>4</sub>, Et<sub>2</sub>O, 0 °C; h) (Boc)<sub>2</sub>O, Et<sub>3</sub>N, CH<sub>2</sub>Cl<sub>2</sub>, r.t., 2 steps = 39%; i) PPTS, MeOH, r.t., 49%; j) H<sub>2</sub>, Lindlar cat., AcOEt, 0 °C, 95%; k) PdCl<sub>2</sub>(MeCN)<sub>2</sub>, THF, 0 °C., 89% (13 : 14 = 85 : 15)

Pd-catalyzed cyclization of **2** was performed as follows. To a stirred solution of 10 mol% PdCl<sub>2</sub>(MeCN)<sub>2</sub> in THF was added a solution of the substrate **2** in THF at 0 °C. The mixture was stirred for 1 h and usual workup gave a mixture of **13** and **14** (89% yield) in a ratio of 85:15<sup>10</sup>. A possible explanation for the stereoselective formation of **13** is as follows (Scheme 2). If the transition states are assumed to be **A** and **B**, the transition state **B**, which leads to **14**, would be disfavored because of non-bonding interaction between the carbamate moiety and the palladium complex.

**Scheme 2**

Next, the conversion of **13** to SS20846A was examined in the following way. The alcohol **15**<sup>11</sup> was prepared in 4 steps (dihydroxylation of olefin ( $\text{OsO}_4$ , NMO; 89% yield), reductive degradation ( $\text{NaIO}_4$ ,  $\text{CH}_2\text{Cl}_2$ ; 87% yield), Wittig reaction, and reduction (DIBAL, THF; 96% yield))<sup>12</sup>. Swern oxidation of **15** followed by Wittig reaction, olefin isomerization, and deprotection gave SS20846A in 22 % overall yield. The physical data for the synthetic product were in accordance with those reported for SS20846A<sup>1a, 13</sup>.



**Scheme 3** a)  $\text{OsO}_4$ , NMO, dioxane, r.t., 89%; b)  $\text{NaIO}_4$ ,  $\text{H}_2\text{O}$ ,  $\text{CH}_2\text{Cl}_2$ , 0 °C, 87%; c)  $(\text{EtO})_2\text{POCH}_2\text{CO}_2\text{Et}$ ,  $\text{NaH}$ , THF, -78 °C, 80%; d) DIBAL, THF, -78 °C, 96%; e)  $(\text{COCl})_2$ ,  $\text{DMSO}$ ,  $\text{Et}_3\text{N}$ ,  $\text{CH}_2\text{Cl}_2$ , -78 °C, 89%; f)  $\text{CH}_3\text{CH}_2\text{PPh}_3\text{Br}$ , *n*-BuLi,  $\text{Et}_2\text{O}$ , -78 °C, 84%; g) TBAF, THF, 0 °C, 97%; h)  $\text{I}_2$ , benzene, r.t., 30%; i)  $\text{CF}_3\text{CO}_2\text{H}$ ,  $\text{CH}_2\text{Cl}_2$ , 0 °C, 100%

In summary, a facile synthesis of SS20846A(1) was accomplished by using intramolecular palladium(II)-catalyzed *N*-alkylation as a key step. This catalytic *N*-alkylation is expected to be useful in the stereoselective synthesis of piperidine alkaloids.

**Acknowledgment.** We are grateful for Dr. Yoshiji Takemoto, Kyoto University, for his kind gift of the spectral data for SS20846A. This work financially supported by the Grant-in Aid for Scientific Research from the Ministry of Education, Science, Sports, and Culture of Japan.

### References and Notes

1. (a) Grabley, S.; Hammann, P.; Kluge, H.; Wink, J.; Kricke, P.; Zeeck, A. *J. Antibiot.* **1991**, *44*, 797.  
 (b) Komoto, T.; Yano, K.; Ono, J.; Okawa, J.; Nakajima, T. *Jpn. Kokai* 35788 ('86), Feb. 20, 1986.
2. Takemoto, Y.; Ueda, S.; Takeuchi, J.; Nakamoto, T.; Iwata, C. *Tetrahedron Lett.* **1994**, *35*, 8821.
3. Isolation; Drautz, H.; Zähner, H.; Kupfer, E.; Keller-Schierlein, W. *Helv. Chem. Acta* **1981**, *64*, 1752.
4. Synthesis; (a) Yamada, H.; Aoyagi, S.; Kibayashi, C. *J. Am. Chem. Soc.* **1996**, *118*, 1054. (b) Kozikowski, A. P.; Park, P. *J. Org. Chem.* **1990**, *55*, 4668. (c) Flann, C. J.; Overman, L. E. *J. Am. Chem. Soc.* **1987**, *109*, 6115. (d) Kozikowski, A. P.; Park, P. *J. Am. Chem. Soc.* **1985**, *107*, 1763.
5. (a) Hirai, Y.; Yokoyama, H. *Yugouka*, **1998**, *56*, 34. (b) Hirai, Y.; Shibuya, K.; Fukuda, Y.; Yokoyama, H.; Yamaguchi, S. *Chem. Lett.* **1997**, 221. (c) Hirai, Y.; Watanabe, J.; Nozaki, T.; Yokoyama, H.; Yamaguchi, S. *J. Org. Chem.* **1997**, *62*, 776. (d) Hirai, Y.; Nagatsu, M. *Chem. Lett.* **1994**, *21*. (e) Hirai, Y.; Terada, T.; Amemiya, Y.; Momose, T. *Tetrahedron Lett.* **1992**, *33*, 7893.
6. For palladium(0)-promoted cyclization, see; (a) Tamaru, Y.; Tanigawa, H.; Itoh, S.; Kimura, M.; Tanaka, S.; Fugami, K.; Sekiyama, T.; Yoshida, Z. *Tetrahedron Lett.* **1992**, *33*, 631. (b) Tamaru, Y.; Hojo, M.; Yoshida, Z. *J. Org. Chem.* **1988**, *53*, 5731. (c) Tamaru, Y.; Hojo, M.; Higashimura, H.; Yoshida, Z. *J. Am. Chem. Soc.* **1988**, *110*, 3994. (d) Tamaru, Y.; Hojo, M.; Kawamura, S.; Yoshida, Z. *J. Org. Chem.* **1986**, *51*, 4089.
7. (a) Takao, K.; Nigawara, Y.; Nishio, E.; Takagi, I.; Maeda, K.; Tadano, K.; Ogawa, S. *Tetrahedron* **1994**, *50*, 5681. (b) Tadano, K.; Takao, K.; Nigawara, Y.; Nishio, E.; Takagi, I.; Maeda, K.; Ogawa, S. *SYNLETT*, **1993**, 565.
8. Yields were not optimised. All new compounds gave satisfactory spectral analyses. The details of these products will be reported elsewhere.
9. Data for **2**;  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  = 5.72 (dtt,  $J$  = 1.5, 6.8, 11.0 Hz, 1H), 5.52 (dtt,  $J$  = 1.2, 7.6, 11.0 Hz, 1H), 4.89 (br, 0.7H), 4.25-4.10 (m, 2H), 3.81 (quint,  $J$  = 5.6 Hz, 1H), 3.20-3.10 (m, 2H), 2.32-2.27 (m, 2H), 1.69-1.56 (m, 2H), 1.41 (s, 9H), 0.87 (s, 9H), 0.04 (s, 6H); IR (neat) 3355, 2931, 2859, 1695  $\text{cm}^{-1}$ ,  $[\alpha]^{28}\text{D}$  -13.3° ( $c$  = 0.75,  $\text{CHCl}_3$ ); Anal. Calcd for  $\text{C}_{18}\text{H}_{37}\text{O}_4\text{NSi}$  : C, 60.13; H, 10.37; N, 3.90. Found : C, 59.94; H, 10.57; N, 3.78.
10. The ratio was measured by  $^1\text{H}$ -NMR analysis.
11. Data for **15**;  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  = 5.70-5.60 (m, 2H), 4.90 (brs, 1H), 4.16 (s, 2H), 4.00 (brd,  $J$  = 13.7 Hz, 1H), 3.80 (tt,  $J$  = 4.4, 11.2 Hz, 1H), 2.84 (td,  $J$  = 2.7, 13.7 Hz, 1H), 1.95-1.88 (m, 1H), 1.80-1.73 (m, 1H), 1.63 (ddd,  $J$  = 6.1, 11.2, 13.0 Hz, 1H), 1.48-1.38 (m, 10H), 0.87 (d,  $J$  = 0.5 Hz, 9H), 0.05 (s, 6H); IR (neat) 3445, 2931, 2859, 1696  $\text{cm}^{-1}$ ;  $[\alpha]^{25}\text{D}$  -17.4° ( $c$  = 0.30,  $\text{CHCl}_3$ )
12. The isomers **15** and **16** (85 : 15) could be separated by silica gel column chromatography.
13.  $[\alpha]^{29}\text{D}$  -15.2° ( $c$  = 0.34,  $\text{CHCl}_3$ ) (lit.  $[\alpha]^{20}\text{D}$  -15° ( $c$  = 1.00,  $\text{CHCl}_3$ ))<sup>1a</sup>